Zacks.com on MSN9h
Novartis Gets CHMP Recommendation for Kisqali in Broader Population
Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...
The American Journal of Managed Care6h
Rise of Innovative Therapies for Breast Cancer Treatment
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses advancements in breast cancer treatment, highlighting CDK4/6 inhibitors and ...
The Times of Northwest Indiana13h
Get Healthy: Advances in diagnostics, treatments tackle breast cancer head on
Advances in breast cancer diagnosis and treatment in the last 70 years have considerably increased the survival rate to 18.7 ...
Hosted on MSN7mon
Study finds adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence
The team found adding ribociclib, a drug that belongs to a class of CDK4/6 inhibitors, to standard hormone therapy not only improved invasive-free survival in women with this type of early-stage ...
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...
Forbes8y
Encouraging Results For Ribociclib In Advanced Breast Cancer
At the European Society for Medical Oncology (ESMO) Congress this week, investigators presented data for a new and potentially important drug, ribociclib (Novartis). This oral medication is ...
Deccan Chronicle2d
Early Detection, Better Survival: The Power of Regular Breast Cancer Screening
The World Health Organization (WHO) reports that approximately 2,000 women are diagnosed with cancer each day. Every day, a ...
Monthly Prescribing Reference1mon
Kisqali Approved for HR-Positive, HER2-Negative Early Breast Cancer
Treatment with ribociclib plus endocrine therapy significantly reduced the risk of disease recurrence by 25.1% compared with endocrine therapy alone. The primary endpoint was invasive disease-free ...
Pharmabiz2d
EMA committee recommends marketing approval for Novartis’ Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
EMA committee recommends marketing approval for Novartis’ Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Saturday, October 19, 202 ...
Medscape1mon
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
The US Food and Drug Administration (FDA) approved ribociclib (Kisqali, Novartis) in combination with an aromatase inhibitor for adult patients with hormone receptor (HR)-positive, human epidermal ...
MedPage Today14d
Nagi El Saghir, MD, on What to Learn From the Final Results of the RIGHT Choice Trial
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Recent clinical trial data suggested a new first-line ...